[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-449749-105":59,"doc-detail-449749-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","tumour-control-eye-retention-and-visual-acuity-after-radiotherapy-for-choroidal-melanoma","Tumour control, eye retention and visual acuity after radiotherapy for choroidal melanoma","","Radiotherapy modalities—including iodine-125 (I125) and ruthenium-106 (Ru106) brachytherapy, and proton beam radiotherapy (PBR)—are assessed for outcomes in choroidal melanoma. A 10-year review evaluates local tumour control, globe retention, and visual acuity (VA), analyzing patient demographics, comorbidities, tumour characteristics, treatment parameters, and VA results. A predictive nomogram is built to estimate final VA using baseline clinical, tumour, and radiation variables, supporting individualized visual prognostication and counselling.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tumour-control-eye-retention-and-visual-acuity-after-radiotherapy-for-choroidal-melanoma/449749/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tumour-control-eye-retention-and-visual-acuity-after-radiotherapy-for-choroidal-melanoma/449749.png","ImageObject",300,407,{"name":92,"@type":93},"mieayamfan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Which radiotherapy modalities were evaluated for choroidal melanoma in this study?","Question",{"text":113,"@type":114},"The study evaluated iodine-125 (I125) brachytherapy, ruthenium-106 (Ru106) brachytherapy, and proton beam radiotherapy (PBR).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were local tumour control, globe retention, and visual acuity outcomes measured?",{"text":118,"@type":114},"Outcomes included local tumour control rates, globe retention rates, and LogMAR visual acuity results after treatment, alongside analysis of patient and tumour factors and treatment parameters.",{"name":120,"@type":111,"acceptedAnswer":121},"What tool was developed to support visual prognostication?",{"text":122,"@type":114},"A predictive nomogram was developed to estimate final visual acuity using baseline clinical, tumour, and radiation parameters.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},449749,1791103374,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":46,"preview_page_count":4},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Original research  \nTo cite: Murtagh P, O’Riordan MM, O’Neill V, et al. Tumour control, eye retention and visual acuity after radiotherapy for choroidal melanoma. BMJ  \nOpen Ophthalmology 2026;11:e002291 . doi:10 . 1136/ bmjophth-2025-002291  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.1136/bmjophth-2025-](10.1136/bmjophth-2025-)[ ](10.1136/bmjophth-2025-)[002291](002291)) .  \nReceived 30 April 2025 Accepted 8 December 2025  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1Royal Victoria Eye and Ear Hospital, Dublin, Ireland 2Research Foundation, Royal Victoria Eye and Ear Hospital, Dublin, Ireland  \n3Liverpool Ocular Oncology Centre, Royal Liverpool University Hospital, Liverpool, UK 4Department of Radiation Oncology, St. Luke’s Hospital, Dublin, Ireland  \n5UCD School of Medicine, University College Dublin, Dublin, Ireland  \n6National Ophthalmic Pathology Laboratory of Ireland—Royal Victoria Eye and Ear Hospital, Dublin, Ireland  \nCorrespondence to  \nMr Patrick Murtagh; murtagp@ [tcd.ie](tcd.ie)  \nTumour control, eye retention and visual acuity after radiotherapy for choroidal melanoma  \nPatrick Murtagh  ,1,2,3,4,5 Matthew M O’Riordan  ,1,2 Valerie O’Neill,1 Moya Cunningham,4 Fiona D’Arcy,1 Antonio Eleuteri,3 Alison Greene,1 Caroline Baily,1 Susan Kennedy,1,2,6 Rumana Hussain,3 Heinrich Heimann,3 Noel Horgan1,2,4,5  \nABSTRACT  \nObjective Radiotherapy modalities such as iodine-125 (I125) and ruthenium-106 (Ru106) brachytherapy and proton beam radiotherapy (PBR) are well established for the treatment of choroidal melanoma. This study aimed to evaluate the rates of local tumour control, globe retention and visual acuity (VA) outcomes in patients with choroidal melanoma treated with I125 or Ru106 brachytherapy or PBR. Methods and analysis A review was conducted of all cases of choroidal melanoma treated with Ru106 or I125 brachytherapy or PBR over a 10-year period. Patient demographics, comorbidities, tumour characteristics, treatment parameters and VA outcomes were analysed. A predictive nomogram was developed to estimate final VA based on baseline clinical, tumour and radiation parameters.  \nResults A total of 310 eyes from 310 patients were included, comprising 175 patients (56 .5%) treated with Ru106, 72 (23 .2%) treated with I125 brachytherapy and 63 (20 .3%) treated with PBR. Local tumour control was achieved in 95.8% of cases. The recurrence rates were 4.0%, 4 .2% and 4 .8% for Ru106, I125 and PBR, respectively. Retention rates were 96 .0% for Ru106, 94.4% for I125 and 95.2% for PBR. LogMAR VA of 1.0 or better was maintained in 50 .9% of Ru106patients, 27 .8% of I125patients and 39.7% of those treated with PBR. Baseline LogMAR VA, tumour volume, radiation dose to the fovea, radiotherapy modality and follow-up duration were significant predictors of final VA and were incorporated into the nomogram. Conclusions Each radiotherapy modality demonstrated high rates of local tumour control and globe retention. The predictive nomogram may serve as a practical tool to support individualised visual prognostication and patient counselling in the management of choroidal melanoma.  \nINTRODUCTION  \nUveal melanoma (UM) originates from melanocytes in the uveal tract and accounts for 85% of all ocular melanomas.1 Tumours occur in the iris (4%), ciliary body (6%) or the choroid (90%) .2 As many as 40% of affected patients develop metastases over a 10-year period.3  \nSubsequent to a diagnosis of UM, treatment options include brachytherapy (with  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Brachytherapy (Ru-106, I-125) and proton beam radiotherapy are well-established modalities to achieve local tumour control in uveal melanoma as an alternative to enucleation. The Collaborative Ocular Melanoma Study demonstrated no surviv","cbCaitUERaDeVHe4","https://ap.wps.com/l/cbCaitUERaDeVHe4","pdf",612636,"English","# Abstract\n## Objective\n## Methods and analysis\n## Results\n## Conclusions\n# Introduction\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy","[{\"question\":\"Which radiotherapy modalities were evaluated for choroidal melanoma in this study?\",\"answer\":\"The study evaluated iodine-125 (I125) brachytherapy, ruthenium-106 (Ru106) brachytherapy, and proton beam radiotherapy (PBR).\"},{\"question\":\"How were local tumour control, globe retention, and visual acuity outcomes measured?\",\"answer\":\"Outcomes included local tumour control rates, globe retention rates, and LogMAR visual acuity results after treatment, alongside analysis of patient and tumour factors and treatment parameters.\"},{\"question\":\"What tool was developed to support visual prognostication?\",\"answer\":\"A predictive nomogram was developed to estimate final visual acuity using baseline clinical, tumour, and radiation parameters.\"}]","Tumour control, eye retention and visual acuity after radiotherapy for choroidal melanoma | PDF",1790731020]